key: cord-0979560-s7chie0t authors: Wu, Jingcheng; Chen, Wenfan; Zhou, Jingjing; Zhao, Wenyi; Chen, Shuqing; Zhou, Zhan title: COVIEdb: A database for potential immune epitopes of coronaviruses date: 2020-05-25 journal: bioRxiv DOI: 10.1101/2020.05.24.096164 sha: af5c989749cc8f5d9f4ca38d79e61bc67c354a46 doc_id: 979560 cord_uid: s7chie0t 2019 novel coronavirus (2019-nCoV) has caused large-scale pandemic COVID-19 all over the world. It’s essential to find out which parts of the 2019-nCoV sequence are recognized by human immune system for vaccine development. And for the prevention of the potential outbreak of similar coronaviruses in the future, vaccines against immunogenic epitopes shared by different human coronaviruses are essential. Here we predict all the potential B/T-cell epitopes for SARS-CoV, MERS-CoV, 2019-nCoV and RaTG13-CoV based on the protein sequences. We found YFKYWDQTY in ORF1ab protein, VYDPLQPEL and TVYDPLQPEL in spike (S) protein might be pan-coronavirus targets for vaccine development. All the predicted results are stored in a database COVIEdb (http://biopharm.zju.edu.cn/coviedb/). Two coronaviruses-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused two large-scale pandemics in the past two decades [1, 2] . Now, the third coronavirus caused pandemic (COVID-19) is ongoing [3, 4] . The 2019 novel coronavirus (2019-nCoV) which was first identified in Wuhan, China in December 2019, from patients with pneumonia is the very coronavirus [5] . Analysis of the viral genome has revealed that 2019-nCoV is phylogenetically close to SARS-CoV [6] , as was named SARS-CoV-2. As of April 27, 2020, 2,980,053 people have been confirmed COVID-19, including 206,569 deaths (∼6.9% fatality rate) all over the world. Because of the less cost-effective than treatment, and reduce morbidity and mortality without long-lasting effects, vaccines are the most effective strategy for preventing infectious diseases [7] . However, there is still no approved vaccines for human coronaviruses (hCoV). There are several types of vaccines are under pre-clinical testing or clinical trials including inactivated vaccine, recombinant subunit vaccine, recombinant vector vaccine, and nucleic acid vaccine. In general, modern vaccines, such as recombinant subunit, peptide, and nucleic acid vaccines, are advantageous over other types of vaccines because of higher safety and less side effect, by inducing the immune system without introducing whole infectious viruses [8] . Nucleic acid vaccines such as DNA vaccines and mRNA vaccines represent an innovative approach by direct injection of plasmids or mRNAs encoding the antigens, accompanied with a wide range of immune responses [9, 10] . These advantages are applied with prophylactic vaccines and therapeutic vaccines to treat infectious diseases and cancers. For the development of modern vaccines, it is of critical importance to identify potential immune epitopes of 2019-nCoV, as well as other infectious pathogens. Considering the seriousness of the recent outbreaks of zoonotic coronaviruses, therapeutic agents and vaccines for pan-coronaviruses should be developed to cope with the hCoV outbreaks in the present and in the future. Here we predict all the potential B/T cell epitopes for SARS-CoV, MERS-CoV and 2019-nCoV to provide potential targets for pan-coronaviruses vaccine development. The prediction are based on their proteins sequences. RaTG13-CoV is added because of its high homology with 2019-nCoV (96% whole genome identity [11] ). All the predicted results are stored in a database named COVIEdb (http://biopharm.zju.edu.cn/coviedb/). The protein sequences of SARS-CoV, MERS-CoV, 2019-nCoV, and RaTG13-CoV of Han Chinese ancestry [12] . The top 20 HLA I alleles of A, B, C subtypes and HLA II alleles with frequency more than 5% are the final HLA datasets (Table S1 ). The B-cell epitopes were predicted by the seven tools embedded in the Immune Epitope Database and Analysis Resource (IEDB) [13] . More specifically, BepiPred-1.0 [14] , BepiPred-2.0 [15] , Chou and Fasman beta turn prediction [16] , Emini surface accessibility scale [17] , Karplus and Schulz flexibility scale [18] , Kolaskar and Tongaonkar antigenicity scale [19] and Parker hydrophilicity prediction [20] are used for predicting amino acid sites belonging to B-cell epitopes. The parameters are all set as default. The sites confirmed by at least five tools would be labeled in red. The thresholds of each tool are in Table S2a . In this study, only amino acids that be confirmed by at least five tools are considered as B-cell epitopes. The T-cell epitopes prediction were divided into two parts. One of them are presented by HLA I allele and would induce the activation of CD8+ T cells. This type of T-cell epitopes were predicted by NetMHCpan 4.0 [21] , MHCflurry [22] and DeepHLApan [23] . Another type of T-cell epitopes presented by HLA II alleles were predicted by MixMHC2pred [24] and NetMHCIIpan [25] , which would induce the activation of CD4+ T cells. The thresholds to defined potential T-cell epitopes of each tool are listed in Table S2b . In the prediction of T-cell epitopes presented by HLA I alleles, all peptides with length range from 8 to 11 were selected and combined with previous HLA I alleles to create HLA-peptide pairs. It's similar to predict that presented by HLA II alleles, with the difference that peptide length range from 15 to 28. Only HLA-peptide pairs satisfied with all thresholds of used tools would be potential T-cell epitopes in this study. The web interface of COVIEdb is made up of five parts, "Home", "B-epitope", "Tepitope", "Peptide", and "Help". A statistical table about the predicted B-cell epitopes and T-cell epitopes are embedded in the "Home" page. The table shows the coronavirus, gene, protein length, the number of amino acids that predicted to be potential B-cell epitopes and T-cell epitopes ( Table 1 ). The number of the predicted epitopes are different but similar among four coronaviruses. The N protein of SARS-CoV is represented as ORF9a and ORF9b as previous state. We can find that many peptides have the potential to be B-cell epitopes or T-cell epitopes, but the prefer targets should be shared by different coronaviruses and we will discuss in the next section. The predicted results of B-cell epitopes could be searched in "B-epitope" page. With the virus and gene selected, the corresponding predicted B-cell epitopes would appear ( Figure 1a The predicted results of T-cell epitopes could be searched in "T-epitope" page. Similar with that in "B-epitope" page, coronavirus and protein are necessary. Besides, the type of T-cell epitopes should also be selected. Because of the numerous pairs of HLA-peptide, we don't show predicted score of all pairs. Only the peptide-HLA pairs which satisfied all thresholds would be showed in this page. Figure 2a and Figure 2b show the searching results when selecting "2019-nCoV, S and HLA I allele", "2019-nCoV, S and HLA II allele", respectively. The searchable data in the "Peptide" page is the combined result of previous predicted B-cell epitopes and T-cell epitopes. In this page, the only selectable parameter is the protein. On click the search button with protein S selected, a table will show ( Figure 3a ). The first column is the protein name. The second column is the peptide that either be predicted T-cell epitopes presented by HLA I alleles (with green background) or HLA II alleles (with yellow background). Amino acids that have been predicted as B cell epitopes by at least five tools are labeled in red. The third is an adjustment score to evaluate the possibility of this peptide to be B cell epitopes. The formulation is as follows: Where L is the length of the peptide, a is the amino acid that belongs to the peptide, is the number of tools convinced that amino acid is part of B-cell epitopes. The fourth/fifth columns are the frequency of HLA I/II alleles that could present the peptide. On click the number would show the detailed HLA alleles (Figure 3b ). The last column is the number of coronavirus that encodes the peptide. The detailed coronavirus and the peptide location in this coronavirus would show on click the number (Figure 3c ). The However, other columns could also be sortable. Though the evolution rate of human coronavirus is fast, we try to find out B/T cell epitopes conserved and shared in different coronaviruses for the pan-coronavirus vaccine development. Based on the predicted B-cell epitopes and T-cell epitopes, we found 77 peptides that exist in all coronaviruses have the potential to induce T-cell activation and 10 of them with B_score larger than 4 (Table S3, Table 2 ). In particular, the peptide YFKYWDQTY from ORF1ab could be presented by 7.33% people, which might be a good candidate for vaccine design. All the T-cell epitopes shared in four coronaviruses are located in ORF1ab. However, the S protein of the coronavirus is the most important protein where the receptor binding domain (RBD) located. So we further investigated the shared epitopes that located in S protein. There are 265 potential epitopes in S protein shared by three coronaviruses and 35 of them with B_score larger than 5 (Table S4 ). The peptides VYDPLQPEL and TVYDPLQPEL even have B_score larger than 6, and they can be presented by 8.26% and 2.44% people, respectively, which indicates their feasibility to be pan-coronavirus vaccine targets. The shared B/T-cell epitopes could be found in the "Peptide" page in COVIEdb and we believe that these results could benefit the vaccine development currently on 2019-nCoV and also the potential coronavirus outbreak in the future. Research groups all over the world are trying to find the way to control 2019-nCoV. Several studies focus on the B/T-cell epitopes for accelerating vaccine development. The group who maintain the database IEDB identified potential targets for immune responses to the 2019-nCoV by sequence homology with closely related SARS-CoV and by a priori epitope prediction using bioinformatics approaches [26] . Tables Table 1. The potential immune epitopes from E, M, N, and S proteins for each coronavirus in the database. Identification of a novel coronavirus in patients with severe acute respiratory syndrome Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia Recent advances in the detection of respiratory virus infection in humans Emerging Viruses without Borders: The Wuhan Coronavirus A novel coronavirus from patients with pneumonia in China Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Advances in mRNA vaccines for infectious diseases A decade after SARS: Strategies for controlling emerging coronaviruses A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice mRNA vaccines-a new era in vaccinology A pneumonia outbreak associated with a new coronavirus of probable bat origin Deep sequencing of the MHC region in the Chinese population contributes to studies of complex disease The immune epitope database (IEDB) 3.0 Improved method for predicting linear B-cell epitopes BepiPred-2.0: Improving sequence-based B-cell epitope prediction using conformational epitopes Prediction of the secondary structure of proteins from their amino acid sequence Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide Prediction of chain flexibility in proteins -A tool for the selection of peptide antigens A semi-empirical method for prediction of antigenic determinants on protein antigens New Hydrophilicity Scale Derived from High-Performance Liquid Chromatography Peptide Retention Data: Correlation of Predicted Surface Residues with Antigenicity and X-ray-Derived Accessible Sites NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data DeepHLApan: A deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity Predicting HLA class II antigen presentation through integrated deep learning NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 Human leukocyte antigen susceptibility map for SARS-CoV-2